Evidence map›Paper›PMID 21655439›Full record

ArticleCommunicative & integrative biology2011

A new twist on plasma membrane repair.

Ronald L Mellgren

Abstract read
In one paragraph

Article in Communicative & integrative biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. The Lysosome Signaling Platform: Adapting With the Times.Frontiers in cell and developmental biology · 2019
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ronald L MellgrenDepartment of Physiology and Pharmacology; University of Toledo; College of Medicine; Toledo, OH USA.

Funding

Role of Calpains in Plasma Membrane RepairR21AR054427 · NIAMS · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MELLGREN, RONALD L · 2008 to 2009
$369k
NIAMS NIH HHS R21 AR054427
6 · The paper itself

Abstract

Cells in multicellular organisms are under constant mechanical stress, and often the plasma membrane (PM) is compromised. Fortunately, there is a vigorous repair mechanism that rapidly (within seconds) reseals the wound site by fusion with an internal membrane patch. Downstream events, remodeling of the injury site and forming replacement PM, must be carried out quickly (within minutes) if a cell is to survive multiple sequential injuries. The repertoire of proteins required to repair breaks (the PM repairome) is one of the major unknowns in this area of research. As an initial approach to defining the PM repairome, a cell surface biotinylation protocol was developed to identify intracellular proteins that become exposed at the site of reversible PM injury. It is likely that at least some of these proteins are important mediators of repair. These initial studies led to a surprising finding, namely the identification of some nuclear and endoplasmic reticulum resident proteins transiently exposed at the surface of cells that ultimately recovered from PM damage. Thus, in reversible mechanical damage to the PM, underlying cellular structures may also be injured, and will also require mechanisms for repair. Other proteins at wound sites were previously identified docking partners for pathogenic bacteria and viruses (vimentin and nucleolin), or found to be upregulated and exposed on the surface of cancer cells (nucleolin and nucleophosmin-1). The new information from these studies may lead to development of novel antimicrobial and antineoplastic drugs.

Indexed as

annexin A1caldesmonERp57HSP47lamin A/Cmaleimide-PEG2-biotinnucleolinnucleophosmin-1plasma membrane repairvimentin

Identifiers

PMID21655439
PMCPMC3104578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.